Astragaloside IV
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 600143

CAS#: 84687-43-4

Description: Astragaloside IV (AS-IV), the major active component extracted from Astragalus membranaceus, has broad application prospects, especially in cardiovascular diseases, digestive diseases, cancer and other modern high incidence, high-risk diseases, and could be developed as a medicine. Protective effects of Astrageloside IV include the cardiovascular system, immune, digestive, nervous system were identified, and the action mechanisms were associated with regulation of the calcium balance, anti-oxydant, antiapoptosis, antivirus, and so on.

Chemical Structure

img
Astragaloside IV
CAS# 84687-43-4
Instruction

Theoretical Analysis

MedKoo Cat#: 600143
Name: Astragaloside IV
CAS#: 84687-43-4
Chemical Formula: C41H68O14
Exact Mass: 784.46
Molecular Weight: 784.970
Elemental Analysis: C, 62.73; H, 8.73; O, 28.54

Price and Availability

Size Price Availability Quantity
5mg USD 330 2 Weeks
10mg USD 580 2 Weeks
Bulk inquiry

Synonym: Astragaloside IV

IUPAC/Chemical Name: (2R,3R,4S,5S,6R)-2-(((2aR,3R,4R,5aS,7R,11aR)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)hexadecahydrocyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.

InChi Key: QMNWISYXSJWHRY-CSXKERSZSA-N

InChi Code: InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20-,21-,22-,23?,24?,25+,26+,27-,28+,29-,30-,31+,32?,33+,34-,37-,38+,39-,40?,41-/m1/s1

SMILES Code: C[C@]12CCC34C[C@@]35CCC(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)C(C)(C)C5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)CC4[C@]1(C)C[C@@H](O)[C@@H]2[C@@]8(C)CC[C@@H](C(C)(O)C)O8

Appearance: solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 784.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xu F, Cui WQ, Wei Y, Cui J, Qiu J, Hu LL, Gong WY, Dong JC, Liu BJ. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res. 2018 Aug 29;37(1):207. doi: 10.1186/s13046-018-0878-0. Erratum in: J Exp Clin Cancer Res. 2023 Mar 23;42(1):70. PMID: 30157903; PMCID: PMC6116548.


2: Zhang J, Wu C, Gao L, Du G, Qin X. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv Pharmacol. 2020;87:89-112. doi: 10.1016/bs.apha.2019.08.002. Epub 2019 Dec 18. PMID: 32089240.


3: Zang Y, Wan J, Zhang Z, Huang S, Liu X, Zhang W. An updated role of astragaloside IV in heart failure. Biomed Pharmacother. 2020 Jun;126:110012. doi: 10.1016/j.biopha.2020.110012. Epub 2020 Mar 23. PMID: 32213428.


4: Xia ML, Xie XH, Ding JH, Du RH, Hu G. Astragaloside IV inhibits astrocyte senescence: implication in Parkinson's disease. J Neuroinflammation. 2020 Apr 6;17(1):105. doi: 10.1186/s12974-020-01791-8. PMID: 32252767; PMCID: PMC7137443.


5: Qian W, Cai X, Qian Q, Zhang W, Wang D. Astragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J Cell Mol Med. 2018 Sep;22(9):4354-4365. doi: 10.1111/jcmm.13725. Epub 2018 Jul 4. PMID: 29971947; PMCID: PMC6111865.


6: Tian L, Zhao JL, Kang JQ, Guo SB, Zhang N, Shang L, Zhang YL, Zhang J, Jiang X, Lin Y. Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling. Front Immunol. 2021 Sep 13;12:740565. doi: 10.3389/fimmu.2021.740565. PMID: 34589089; PMCID: PMC8473681.


7: Chen T, Yang P, Jia Y. Molecular mechanisms of astragaloside‑IV in cancer therapy (Review). Int J Mol Med. 2021 Mar;47(3):13. doi: 10.3892/ijmm.2021.4846. Epub 2021 Jan 15. PMID: 33448320; PMCID: PMC7834967.


8: Wang F, Qian H, Kong L, Wang W, Wang X, Xu Z, Chai Y, Xu J, Kang Q. Accelerated Bone Regeneration by Astragaloside IV through Stimulating the Coupling of Osteogenesis and Angiogenesis. Int J Biol Sci. 2021 Apr 24;17(7):1821-1836. doi: 10.7150/ijbs.57681. PMID: 33994865; PMCID: PMC8120474.


9: Tan YQ, Chen HW, Li J. Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases. Drug Des Devel Ther. 2020 Sep 15;14:3731-3746. doi: 10.2147/DDDT.S272355. PMID: 32982178; PMCID: PMC7507407.


10: Zhang X, Qu H, Yang T, Liu Q, Zhou H. Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway. Cell Cycle. 2022 Nov;21(21):2309-2322. doi: 10.1080/15384101.2022.2093598. Epub 2022 Jun 30. PMID: 35770948; PMCID: PMC9586672.


11: Shi H, Zhou P, Gao G, Liu PP, Wang SS, Song R, Zou YY, Yin G, Wang L. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway. J Food Biochem. 2021 Jul;45(7):e13757. doi: 10.1111/jfbc.13757. Epub 2021 May 25. PMID: 34032295.


12: Wang E, Wang L, Ding R, Zhai M, Ge R, Zhou P, Wang T, Fang H, Wang J, Huang J. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. Pharmacol Res. 2020 Jul;157:104831. doi: 10.1016/j.phrs.2020.104831. Epub 2020 Apr 24. PMID: 32339782.


13: Wang N, Zhang X, Ma Z, Niu J, Ma S, Wenjie W, Chen J. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(-/-) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling. Biomed Pharmacother. 2020 Mar;123:109729. doi: 10.1016/j.biopha.2019.109729. Epub 2019 Dec 27. PMID: 31887543.


14: Feng H, Zhu X, Tang Y, Fu S, Kong B, Liu X. Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome‑mediated inflammation. Int J Mol Med. 2021 Aug;48(2):164. doi: 10.3892/ijmm.2021.4996. Epub 2021 Jul 19. PMID: 34278447; PMCID: PMC8262660.


15: Wu Y, Xiao W, Pei C, Wang M, Wang X, Huang D, Wang F, Wang Z. Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway. Int Immunopharmacol. 2021 Feb;91:107290. doi: 10.1016/j.intimp.2020.107290. Epub 2020 Dec 29. PMID: 33383446.


16: Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H, Tang Y. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway. J Ethnopharmacol. 2020 Mar 1;249:112404. doi: 10.1016/j.jep.2019.112404. Epub 2019 Nov 15. PMID: 31739105.


17: Luo LF, Guan P, Qin LY, Wang JX, Wang N, Ji ES. Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling. Mol Cell Biochem. 2021 Jul;476(7):2603-2611. doi: 10.1007/s11010-021-04112-6. Epub 2021 Mar 3. PMID: 33656642.


18: Wang Z, Wu Y, Pei C, Wang M, Wang X, Shi S, Huang D, Wang Y, Li S, Xiao W, He Y, Wang F. Astragaloside IV pre-treatment attenuates PM2.5-induced lung injury in rats: Impact on autophagy, apoptosis and inflammation. Phytomedicine. 2022 Feb;96:153912. doi: 10.1016/j.phymed.2021.153912. Epub 2021 Dec 27. PMID: 35026504.


19: Cheng S, Zhang X, Feng Q, Chen J, Shen L, Yu P, Yang L, Chen D, Zhang H, Sun W, Chen X. Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway. Life Sci. 2019 Jun 15;227:82-93. doi: 10.1016/j.lfs.2019.04.040. Epub 2019 Apr 17. PMID: 31004658.


20: Xing L, Fang J, Zhu B, Wang L, Chen J, Wang Y, Huang J, Wang H, Yao X. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy. Life Sci. 2021 Mar 15;269:119068. doi: 10.1016/j.lfs.2021.119068. Epub 2021 Jan 18. PMID: 33476631.